Nov. 17, 2025
UCalgary and Providence Therapeutics kick off new partnership
The University of Calgary has partnered with Providence Therapeutics to accelerate academic research into new molecular targets for life-saving vaccines and therapeutics.
The UCalgary And Providence Therapeutics United for translational Research Excellence (CAPTURE) program will focus on new treatments in oncology, infectious diseases and veterinary medicine.
“This exceptional opportunity for our researchers to work with Providence to rapidly deploy new therapeutics for clinical testing is an exemplar of why our university is a leader in research and innovation,” says William Ghali, Vice-President (Research), UCalgary.
Headquartered in Calgary, Providence has created a robust, scalable, validated and cost-effective mRNA platform that can be leveraged to produce mRNA vaccines.
Researchers at UCalgary will nominate promising disease targets, and, if selected, they’ll serve as principal investigators in research that could quickly advance new treatment options for patients.
“Providence is excited to work shoulder to shoulder with researchers at UCalgary to tackle serious health issues impacting Canadians,” says Brad Sorenson, BEd’98, BSc’01, founder and CEO of Providence Therapeutics.
“Building on our successful collaboration in serious late-stage cancers, we hope that, by formalizing this partnership at an institutional level, Providence and UCalgary will continue to drive early access to cutting-edge breakthroughs in a range of disease settings.”
The CAPTURE program is now open for expressions of interest from UCalgary researchers and can be accessed through the Industry Liaison Office (Research).
UCalgary and Providence Therapeutics Partnership Kick-off
On November 13, UCalgary and Providence Therapeutics celebrated the new industry partnership of the CAPTURE program open to UCalgary researchers.
Photos: Riley Brandt, University of Calgary
Founded in 2015 and headquartered in Calgary, Providence Therapeutics Holdings Inc. is a clinical-stage biotechnology company pioneering mRNA-based therapeutics and vaccines with a focus on infectious diseases and oncology programs. Leveraging their proprietary INTENT™ Lipid Nanoparticle (LNP) delivery system, the company has developed its programs both internally and in collaboration with academic and industry partners across diverse scientific fields. For more information, visit www.providencetherapeutics.com.
The Industry Liaison Office – Research (ILO-R) at UCalgary facilitates collaboration between university researchers and industry by actively connecting faculty with companies, aligning research expertise and facilities with business needs, and managing strategic partnerships.